drugset / Trial / NCT01851096
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
Heat shock protein 90 (Hsp90) is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-10
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNX-5422 | Small molecule | 50 mg/m2 | — |
| Background | Erlotinib | Small molecule | 150 mg | — |